Cost-Effectiveness of Early Treatment With Originator Biologics or Their Biosimilars After Methotrexate Failure in Patients With Established Rheumatoid Arthritis
Advances in Therapy - United States
doi 10.1007/s12325-019-00986-7
Full Text
Open PDFAbstract
Available in full text
Date
May 30, 2019
Authors
Publisher
Springer Science and Business Media LLC